Association Between Polymorphisms in the Purinergic P2Y12 Receptor Gene and Severity of Both Cancer Pain and Postoperative Pain | Zendy

Masahiko Sumitani | Zendy; Daisuke Nishizawa | Zendy; Makoto Nagashima | Zendy; Kazutaka Ikeda | Zendy; Hiroaki Abe | Zendy; Ryoji Kato | Zendy; Hiroshi Ueda | Zendy; Yoshitsugu Yamada | Zendy

Open Access

Association Between Polymorphisms in the Purinergic P2Y12 Receptor Gene and Severity of Both Cancer Pain and Postoperative Pain

Author(s) -

Masahiko Sumitani,

Daisuke Nishizawa,

Makoto Nagashima,

Kazutaka Ikeda,

Hiroaki Abe,

Ryoji Kato,

Hiroshi Ueda,

Yoshitsugu Yamada

Publication year - 2017

Publication title -

pain medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.893

H-Index - 97

eISSN - 1526-4637

pISSN - 1526-2375

DOI - 10.1093/pm/pnx102

Subject(s) - single nucleotide polymorphism , cancer pain , medicine , purinergic receptor , chronic pain , genotype , linkage disequilibrium , genotyping , snp , opioid , pain medicine , bioinformatics , cancer , oncology , anesthesia , biology , genetics , gene , adenosine , anesthesiology , physical therapy , receptor

Despite the widespread use of opioids for the treatment of cancer pain, results from several surveys consistently show that pain is still prevalent in some patients with malignant diseases. The purinergic P2Y12 receptor is a primary site leading to microglial activation and hyperalgesic pain behaviors and is considered a key regulator in the prevention of the aggravation of clinical pain conditions. Genetic variability in the P2RY12 gene may contribute to individual differences in pain and opioid sensitivity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research